{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:43:55Z","timestamp":1791247435070,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.tmrv.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T02:18:56Z","timestamp":1663121936000},"page":"188-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Changing Paradigms in ITP Management: Newer Tools for an Old Disease"],"prefix":"10.1016","volume":"36","author":[{"given":"Debbie","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanny","family":"Al-Samkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7814-9150","authenticated-orcid":false,"given":"Sandhya R.","family":"Panch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2022.08.003_bib0001","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0955-3886(98)00036-8","article-title":"The history of idiopathic thrombocytopenic purpura (ITP)","volume":"19","author":"Blanchette","year":"1998","journal-title":"Transfus Sci"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0002","first-page":"636","article-title":"Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. 1951","volume":"115","author":"Harrington","year":"1990","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0003","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0004","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","article-title":"Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?","volume":"104","author":"Lucchini","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0005","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0006","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.704093","article-title":"Comparative efficacy and safety of Thrombopoietin receptor agonists in adults with thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trial","volume":"12","author":"Deng","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0008","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/369565a0","article-title":"Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo","volume":"369","author":"Lok","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0009","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.hoc.2009.09.001","article-title":"Thrombopoietin and platelet production in chronic immune thrombocytopenia","volume":"23","author":"Kuter","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0010","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0011","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP","volume":"355","author":"Bussel","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0012","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-021-01047-9","article-title":"A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0013","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1182\/blood-2017-01-761262","article-title":"A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy","volume":"130","author":"Kong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0014","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0016","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2020-142788","article-title":"Efficacy analyses from the immune thrombocytopenia (ITP) clinical development program for avatrombopag: comparisons with placebo and eltrombopag","volume":"136","author":"Tarantino","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0017","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0018","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0019","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/09537104.2021.1881952","article-title":"Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension","volume":"33","author":"Al-Samkari","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0020","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/bjh.18081","article-title":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study","volume":"197","author":"Al-Samkari","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719837906","article-title":"Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia","volume":"10","author":"Gonz\u00e1lez-Porras","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0022","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000510676","article-title":"Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified delphi panel","volume":"144","author":"Cooper","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0023","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12185-019-02638-6","article-title":"Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series","volume":"110","author":"Poston","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211048361","article-title":"Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations","volume":"12","author":"Carpenedo","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0025","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2008.07464.x","article-title":"Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials","volume":"144","author":"George","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0026","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/ajh.23163","article-title":"Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care","volume":"87","author":"Kuter","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0027","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2147\/CEOR.S177338","article-title":"Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia","volume":"10","author":"Tremblay","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0028","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0029","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2012-09-455691","article-title":"Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia","volume":"121","author":"Gudbrandsdottir","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0030","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0031","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.13622","article-title":"Mycophenolate mofetil therapy for severe immune thrombocytopenia","volume":"171","author":"Taylor","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0032","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1034\/j.1600-0609.2003.00076.x","article-title":"Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura","volume":"70","author":"Hou","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0033","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ajh.20992","article-title":"Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura","volume":"83","author":"McMillan","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0034","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.26036","article-title":"Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): impact of ITP on health-related quality of life","volume":"96","author":"Cooper","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0035","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(21)00030-2","article-title":"Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial","volume":"8","author":"Sun","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0036","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2352-3026(21)00240-4","article-title":"All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"8","author":"Huang","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0037","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0038","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/bjh.16959","article-title":"Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia","volume":"190","author":"Boccia","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0039","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fimmu.2016.00078","article-title":"Targeting Syk in autoimmune rheumatic diseases","volume":"7","author":"Deng","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0040","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","article-title":"Preclinical efficacy and anti-inflammatory mechanisms of action of the bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease","volume":"206","author":"Langrish","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0041","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an Oral BTK Inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0042","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0043","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0044","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0045","unstructured":"Argenx. https:\/\/www.argenx.com\/news\/argenx-announces-positive-phase-3-data-advance-trial-vyvgartr-efgartigimod-alfa-fcab-adults 2022 August 28th 2022."},{"key":"10.1016\/j.tmrv.2022.08.003_bib0046","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0047","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-based antibody depletion for refractory autoimmune hematological diseases","volume":"1","author":"Ratnasingam","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0048","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1097\/MJT.0000000000000517","article-title":"Bortezomib for refractory immune-mediated thrombocytopenia purpura","volume":"25","author":"Beckman","year":"2018","journal-title":"Am J Ther"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0049","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjh.13648","article-title":"Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor","volume":"173","author":"Peerschke","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2022.08.003_bib0050","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2019-122210","article-title":"Inhibition of the classical pathway of complement with Sutimlimab in chronic immune thrombocytopenic purpura patients without adequate response to two or more prior therapies","volume":"134","author":"Broome","year":"2019","journal-title":"Blood"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796322000414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796322000414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:19:34Z","timestamp":1760138374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796322000414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0887796322000414"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2022.08.003","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changing Paradigms in ITP Management: Newer Tools for an Old Disease","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}